Eli Lilly stock is considered an undervalued healthcare stock to buy due to its strong innovation pipeline and significant revenue growth from new treatments.
Source Post
Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy? | LLY Stock Analysis
Jun 26, 2026
Eli Lilly (LLY) stock has seen recent gains but is still considered undervalued by some investors. The company's strength lies in its innovation and development of new treatments for diseases, including positive phase three results for Jaypirca in leukemia and promising weight loss drug retatrutide. Eli Lilly's strong profit margins and cash flow from operations indicate successful R&D efforts, making it an attractive long-term investment despite potential regulatory discussions.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
LLYbuy opened Jun 26, 2026
-2.40%